Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $227.11 | 9 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $133.48 | 3 | $0 (2023) |
| Novo Nordisk Inc | $31.26 | 2 | $0 (2023) |
| PFIZER INC. | $17.14 | 1 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.24 | 1 | $0 (2021) |
| Xeris Pharmaceuticals, Inc. | $14.97 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $14.02 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14.97 | 1 | Xeris Pharmaceuticals, Inc. ($14.97) |
| 2023 | $130.05 | 3 | ABBVIE INC. ($115.60) |
| 2022 | $34.69 | 2 | ABBVIE INC. ($17.88) |
| 2021 | $47.40 | 3 | PFIZER INC. ($17.14) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/26/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Diabetes | ||||||
| 08/29/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: Diabetes | ||||||
| 02/23/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $98.97 | General |
| Category: NEUROSCIENCE | ||||||
| 01/20/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: NEUROSCIENCE | ||||||
| 09/14/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: NEUROSCIENCE | ||||||
| 09/13/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Diabetes | ||||||
| 11/18/2021 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.02 | General |
| Category: Cardiovascular | ||||||
| 07/09/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), TRIJARDY XR | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: DIABETES | ||||||
| 03/25/2021 | PFIZER INC. | PREMARIN (Drug), COLOGUARD DNA CAPTURE REAGENTS, REYVOW | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: WOMENS HEALTH | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 551 | 1,827 | $138,443 | $49,252 |
| 2022 | 11 | 446 | 961 | $86,486 | $31,914 |
| 2021 | 25 | 2,065 | 3,914 | $276,595 | $81,540 |
| 2020 | 32 | 2,464 | 4,711 | $327,616 | $87,597 |
All Medicare Procedures & Services
79 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 147 | 556 | $101,748 | $39,058 | 38.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 133 | 316 | $5,056 | $2,638 | 52.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 51 | $6,936 | $2,412 | 34.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 17 | 17 | $3,536 | $1,771 | 50.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 50 | 182 | $6,552 | $1,460 | 22.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $4,420 | $1,066 | 24.1% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 44 | 91 | $2,275 | $498.57 | 21.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 19 | 19 | $1,558 | $147.68 | 9.5% |
| 81003 | Automated urinalysis test | Office | 2023 | 23 | 44 | $572.00 | $96.80 | 16.9% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 20 | 204 | $4,140 | $73.84 | 1.8% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 47 | 330 | $1,650 | $29.32 | 1.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 111 | 250 | $46,828 | $19,063 | 40.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 66 | 114 | $15,547 | $6,037 | 38.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 30 | $7,800 | $2,695 | 34.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 16 | 16 | $3,328 | $1,674 | 50.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 16 | 16 | $2,864 | $982.59 | 34.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 31 | 85 | $3,060 | $689.02 | 22.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 102 | 171 | $2,736 | $504.36 | 18.4% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2022 | 27 | 42 | $1,050 | $202.81 | 19.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 12 | 80 | $2,400 | $30.29 | 1.3% |
| 81003 | Automated urinalysis test | Office | 2022 | 11 | 11 | $143.00 | $24.23 | 16.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 25 | 146 | $730.00 | $12.66 | 1.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 235 | 628 | $114,924 | $40,630 | 35.4% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2021 | 207 | 366 | $19,764 | $6,149 | 31.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 220 | 464 | $25,056 | $4,900 | 19.6% |
About Crystal Hancock, NP
Crystal Hancock, NP is a Family healthcare provider based in Trenton, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/20/2014. The National Provider Identifier (NPI) number assigned to this provider is 1881019305.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Crystal Hancock, NP has received a total of $227.11 in payments from pharmaceutical and medical device companies, with $14.97 received in 2024. These payments were reported across 9 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($227.11).
As a Medicare-enrolled provider, Hancock has provided services to 5,526 Medicare beneficiaries, totaling 11,413 services with total Medicare billing of $250,303. Data is available for 4 years (2020–2023), covering 79 distinct procedure/service records.
Practice Information
- Specialty Family
- Location Trenton, GA
- Active Since 02/20/2014
- Last Updated 10/19/2015
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1881019305
Products in Payments
- VRAYLAR (Drug) $133.48
- PREMARIN (Drug) $17.14
- Rybelsus (Drug) $16.81
- JARDIANCE (Drug) $16.24
- GVOKE HYPOPEN (Drug) $14.97
- Ozempic (Drug) $14.45
- ELIQUIS (Drug) $14.02
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Trenton
William Simpson, Fnp, FNP
Family — Payments: $27,928
Mrs. Wanda Graupman, Np-C, NP-C
Family — Payments: $6,510
Ann Gonzalez, Crnp, CRNP
Family — Payments: $6,025
Ms. Sara Young, Np, NP
Family — Payments: $3,648
Michele Page, Fnp-C, FNP-C
Family — Payments: $1,874
Catherine Mcnamara
Family — Payments: $1,758